

Board of Governors of the Federal Reserve System, May 3, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-11348 Filed 5-8-95; 8:45 am]

BILLING CODE 6210-01-F

Norwest Corporation; Notice of Application to Engage de novo in Permissible Nonbanking Activities

The company listed in this notice has filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 23, 1995.

A. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Norwest Corporation*, Minneapolis, Minnesota; to engage *de novo* through its subsidiary, *Norwest Ventures, Inc.*, Des Moines, Iowa, in a joint venture with *Conerstone Mortgage, Ho-Ho-Kus*, New

Jersey, and engage in the residential mortgage lending business, including activities such as prequalification, mortgage loan origination and processing and closing loans, pursuant § 225.25(b)(1) of the Board's Regulation Y. The geographic scope of this activity is Paramus, New Jersey, and the surrounding area.

Board of Governors of the Federal Reserve System, May 3, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-11349 Filed 5-8-95; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[CDC-538]

Cooperative Agreement for the Hepatitis B Coalition Notice of Availability of Funds for Fiscal Year 1995

Introduction

The Centers for Disease Control and Prevention (CDC), National Immunization Program (NIP), announces the availability of cooperative agreement funds in fiscal year (FY) 1995 to assist the Hepatitis B Coalition in promoting hepatitis B prevention activities. Approximately \$150,000 is available in FY 1995 to fund one cooperative agreement award. It is expected the award will begin on or about September 1, 1995, for a 12-month budget period within a project period of up to five years. Continuation awards within the project period will be made on the basis of satisfactory progress and the availability of funds. The funding estimate may vary and is subject to change.

The purpose of this cooperative agreement will be to improve: (1) Provider knowledge about hepatitis B prevention through the development and dissemination of information and educational materials, and the implementation of promotional activities for health care professionals; (2) community awareness of the need for hepatitis B screening and vaccination through the development and dissemination of information and educational materials, and the implementation of promotional activities for specific target audiences within the general population; and (3) communication and facilitate partnerships between State and local health departments, private provider

organizations, hospitals, voluntary groups, and other health care coalitions to increase awareness about hepatitis B prevention activities. By strategically focusing resources through this cooperative agreement, efforts to reach national hepatitis B vaccination coverage levels of 70% by 1996 and 90% by 1998 will be greatly enhanced.

CDC will provide technical assistance in the development of programs by providing scientific collaboration for appropriate aspects of the activities, including information on disease impact, vaccination coverage levels, and prevention strategies; and assisting in reporting and validating relevant hepatitis B information made available to Federal, State, local health agencies, health care providers, and volunteer organizations.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to the priority area of Immunization and Infectious Diseases. (For ordering a copy of Healthy People 2000, see the section **WHERE TO OBTAIN ADDITIONAL INFORMATION.**)

Authority

This program is authorized under the Public Health Service Act, Section 317(k)(3) [42 U.S.C. 247b(k)(3)], as amended.

Smoke-Free Workplace

PHS strongly encourages all grant recipients to provide a smoke-free workplace and to promote the nonuse of all tobacco products, and Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

Eligible Applicants

Assistance will be provided only to the Hepatitis B Coalition for this project. No other applications will be solicited. The Program Announcement and application kit have been sent to the Hepatitis B Coalition.

The Hepatitis B Coalition is the most appropriate entity to conduct work under this cooperative agreement because:

1. The Hepatitis B Coalition represents an established collaboration among professional, voluntary, and public and private sector organizations with a history of combining resources, sharing information, developing and

distributing educational materials, and supporting activities that advocate preventing hepatitis B virus (HBV) infection through vaccination, education, testing, and treatment.

The Coalition's information and educational efforts are disease specific and its mission is to improve hepatitis B vaccination coverage levels and reduce the incidence of HBV infection. These activities are national in scope and are not limited to local or regional entities.

2. This Coalition is the only such organization whose primary objective is to provide hepatitis B information and education to health care providers to improve their immunization practices, and to the public to increase awareness and knowledge of the disease. The Coalition has also demonstrated success in reaching Southeast Asian communities, a high risk group that has not received culturally appropriate education, outreach, and testing/vaccination services from other health care providers. In addition, the Coalition has developed and tested effective bilingual educational materials for Asian/Pacific Islanders based on their cultural, religious, and political beliefs.

3. The Coalition has a demonstrated history of regular written communications such as newsletters or "Dear Colleague" letters. It has sponsored and promoted regularly scheduled local, regional, and national meetings of its individual members to share information, transfer skills, and promote initiatives pertaining to the prevention of HBV infection. It successfully motivates other organizations to participate in Coalition activities.

4. Through emphasis on public and provider education concerning hepatitis B prevention issues, the Coalition has demonstrated leadership in building relationships with national organizations, private and public sector non-profit health care organizations, professional health associations, volunteer groups, advocacy groups, minority organizations, and government entities.

No other organization devoted to addressing the wide-ranging needs for education and professional development on hepatitis B prevention exists that has the experience and demonstrated program successes, the national reach, and the organizational structure to provide to those audiences who will benefit the most, the information and education required to improve vaccination coverage levels and reduce disease incidence. The past performance and ongoing success of this

Coalition make it uniquely qualified for this project.

Executive Order 12372

This applicant is not subject to Intergovernmental Review of Federal Programs as governed by Executive Order 12372.

Public Health System Reporting Requirements

This program is not subject to the Public Health System Reporting Requirements.

Catalog of Federal Domestic Assistance Number

The Catalog of Federal Domestic Assistance Number for this project is 93.185.

Where To Obtain Additional Information

If you are interested in obtaining additional information about this project, please reference Announcement Number 538, and contact Lisa Tamaroff, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., MS E-13, Atlanta, GA 30305, telephone (404) 842-6796.

A copy of Healthy People 2000 (Full Report; Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report; Stock No. 017-001-00473-1) may be obtained through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: May 3, 1995.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-11351 Filed 5-8-95; 8:45 am]

BILLING CODE 4163-18-P

Food and Drug Administration

[FDA 225-94-6001]

Memorandum of Understanding Between the Food and Drug Administration and the National Institute of Standards and Technology

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the National Institute of Standards and Technology (NIST). The purpose of the MOU is to collaborate in a program to

develop standard reference materials (SRM's) for a variety of biomaterials.

DATES: The agreement became effective February 14, 1994.

FOR FURTHER INFORMATION CONTACT: Sandy Cordes, Center for Devices and Radiological Health (HFZ-20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-3516.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which states that all written agreements and memoranda of understanding between FDA and others shall be published in the **Federal Register**, the agency is publishing notice of this memorandum of understanding.

Dated: May 2, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

Memorandum of Understanding Between the National Institute of Standards and Technology and the Food and Drug Administration, November 10, 1993

This memorandum of understanding (MOU) between the U.S. Department of Commerce, National Institute of Standards and Technology (NIST) and the U.S. Department of Health and Human Services, Food and Drug Administration (FDA) has been implemented to facilitate the development of Standard Reference Materials (SRMs) for materials used in medical implant applications. These materials are commonly referred to as biomaterials.

Background

The National Institute of Standards and Technology has, as one of its long-standing programs, the development of and marketing of standard reference materials required for precision metrology in a variety of applications. The Food and Drug Administration is responsible for the regulation of medical devices made from biomaterials. For many of these biomaterials, it has been determined that subtle variations in chemical composition, trace element content, crystalline structure or morphology, homogeneity, surface topology and chemistry, and other material characteristics can significantly alter the response of living tissue (i.e. the body) to a material, either as an implant or by external contact. Thus the availability of well-characterized reference materials for use in generating baseline data on the biological performance of a biomaterial, is essential.

Overview

The parties to this MOU will collaborate in a program to develop (SRMs) for a variety of biomaterials. This collaboration will enable NIST to enhance its activities in the biomedical area and increase the utility of its SRM Program by addressing many critical measurement needs in the assessment of biomaterials and medical devices. The SRM Program at NIST will gain marketable SRMs for biomaterials, an area in which NIST has had no previous products. At the same time,